Expanded Germline Testing Reveals Clinically Relevant Overlap Across Hereditary Cancer Syndromes

Background: Despite the widespread implementation of BRCA1 and BRCA2 and mismatch repair testing, a substantial proportion of patients with suspected hereditary cancer remain without a molecular diagnosis. We evaluated the clinical utility of expanded germline testing in individuals with hereditary breast, ovarian and colorectal cancer susceptibility. Methods: Patients with suspected hereditary breast, ovarian, and colorectal cancer syndromes underwent multigene panel testing using the Ion S5™ System. Pathogenic and likely pathogenic variants were correlated with clinical and histopathological features. Results: Expanded germline testing identified clinically actionable pathogenic variants beyond BRCA1/2 and mismatch repair genes in 13% (146/1126) of high-risk families. Homologous recombination repair genes represented the largest subgroup of findings, with ATM emerging as the most prevalent non-BRCA susceptibility gene (3.7%). Among individuals fulfilling hereditary breast and ovarian cancer criteria, pathogenic variants in Lynch syndrome and polyposis genes were detected in 1.6% of cases, highlighting the limitations of phenotype-driven testing strategies. Additional pathogenic variants were identified in TP53, CDH1, CDKN2A, FANCM, NF1 and NBN, while concurrent mutations were detected in 1.15% of families. Conclusions: These findings demonstrate that a clinically relevant proportion of hereditary cancer susceptibility lies outside the classical BRCA1/2 and mismatch repair gene framework. Incorporating non-canonical susceptibility genes into routine testing increases diagnostic yield, identifies actionable cancer risk alleles and may refine surveillance, prevention and personalised management strategies in high-risk individuals.

Authors

Institutions

Publication Details

Journal
Medical Sciences
Published
2026-11-16
DOI
https://doi.org/10.3390/medsci14070790
Primary Topic
BRCA gene mutations in cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Expanded Germline Testing Reveals Clinically Relevant Overlap Across Hereditary Cancer Syndromes

Noemí Martínez, Lucía Mateo, Amaya Olaverri, Enrique Lastra et al.
Medical Sciences
BRCA gene mutations in cancer
article

Expanded Germline Testing Reveals Clinically Relevant Overlap Across Hereditary Cancer Syndromes

Noemí Martínez, Lucía Mateo, Amaya Olaverri, Enrique Lastra, Mónica Arranz-Ledo, Mar Infante, Lara Hernández, Raquel Ferreira, César Gutiérrez, Mercedes Durán
article en

Abstract

Background: Despite the widespread implementation of BRCA1 and BRCA2 and mismatch repair testing, a substantial proportion of patients with suspected hereditary cancer remain without a molecular diagnosis. We evaluated the clinical utility of expanded germline testing in individuals with hereditary breast, ovarian and colorectal cancer susceptibility. Methods: Patients with suspected hereditary breast, ovarian, and colorectal cancer syndromes underwent multigene panel testing using the Ion S5™ System. Pathogenic and likely pathogenic variants were correlated with clinical and histopathological features. Results: Expanded germline testing identified clinically actionable pathogenic variants beyond BRCA1/2 and mismatch repair genes in 13% (146/1126) of high-risk families. Homologous recombination repair genes represented the largest subgroup of findings, with ATM emerging as the most prevalent non-BRCA susceptibility gene (3.7%). Among individuals fulfilling hereditary breast and ovarian cancer criteria, pathogenic variants in Lynch syndrome and polyposis genes were detected in 1.6% of cases, highlighting the limitations of phenotype-driven testing strategies. Additional pathogenic variants were identified in TP53, CDH1, CDKN2A, FANCM, NF1 and NBN, while concurrent mutations were detected in 1.15% of families. Conclusions: These findings demonstrate that a clinically relevant proportion of hereditary cancer susceptibility lies outside the classical BRCA1/2 and mismatch repair gene framework. Incorporating non-canonical susceptibility genes into routine testing increases diagnostic yield, identifies actionable cancer risk alleles and may refine surveillance, prevention and personalised management strategies in high-risk individuals.

Medical SciencesVol. 14(7)
Hospital Universitario de Burgos (ES), Instituto de Biomedicina y Genética Molecular de Valladolid (ES), Hospital Universitario Río Hortega (ES)
BRCA gene mutations in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon